The Evolution of Methotrexate as a Treatment for Ectopic Pregnancy and Gestational Trophoblastic Neoplasia: A Review
Author(s) -
Monika Skubisz,
Stephen Tong
Publication year - 2012
Publication title -
isrn obstetrics and gynecology
Language(s) - English
Resource type - Journals
eISSN - 2090-4444
pISSN - 2090-4436
DOI - 10.5402/2012/637094
Subject(s) - methotrexate , choriocarcinoma , medicine , ectopic pregnancy , gestational trophoblastic neoplasia , folic acid , pregnancy , antimetabolite , folic acid antagonists , antifolate , obstetrics , chemotherapy , gynecology , biology , genetics
Methotrexate was developed in 1949 as a synthetic folic acid analogue to compete with folic acid and thus interfere with cell replication. While initially developed as a potential treatment for acute lymphoblastic leukaemia, a serendipitous observation led to methotrexate's use to effect the dramatic cure of a case of advanced choriocarcinoma. This prompted the exploration for the potential of methotrexate to treat other conditions involving disordered trophoblastic tissue. Methotrexate has subsequently revolutionized the treatment of two pregnancy-related conditions—gestational trophoblastic neoplasia and ectopic pregnancy. This article reviews the development of modern treatment protocols that use methotrexate to medically treat these two important gynaecological conditions.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom